PCRX will trade to $65 by Feb 2014, giving it a market cap of $2.2B. Interestingly, DRRX has a PDUFA date in Feb for their version of Exparel (called Posidur-- more bupivacaine and more opioid reduction in their pivotal trials). If Posidur is approved, DRRX will trade to $7-8. Buy it now for the run up, hold through PDUFA if you have balls (either way you make money). My hunch is that DRRX will report a partnership before the PDUFA date so the time to buy is now. Place your bets!